FDA Review Finds TEVA Pharmaceuticals USA's Generic Wellbutrin Safe, Effective
Teva commends the actions taken by the FDA, to assure patients that Budeprion is both "bioequivalent and therapeutically equivalent to (interchangeable with) Wellbutrin XL 300 mg." Teva is pleased that after their thorough review of Budeprion, the FDA has released this important information to the public.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.
The full FDA Report can be viewed at: http://www.fda.gov/cder/drug/infopage/bupropion/TE_review.htm.
Teva Pharmaceuticals USA Denise Bradley, 215-591-8974 email@example.com